SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001437749-24-026908
Filing Date
2024-08-15
Accepted
2024-08-14 18:22:56
Documents
20
Period of Report
2024-08-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K nrxp20240814d_8k.htm   iXBRL 8-K 27855
2 EXHIBIT 99.1 ex_714996.htm EX-99.1 49780
7 pic1.jpg GRAPHIC 2716
8 pic2.jpg GRAPHIC 23290
9 pic3.jpg GRAPHIC 26508
10 pic4.jpg GRAPHIC 13251
11 pic5.jpg GRAPHIC 20735
  Complete submission text file 0001437749-24-026908.txt   359522

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA nxrp-20240814.xsd EX-101.SCH 3911
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nxrp-20240814_def.xml EX-101.DEF 13473
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE nxrp-20240814_lab.xml EX-101.LAB 17730
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nxrp-20240814_pre.xml EX-101.PRE 13450
22 EXTRACTED XBRL INSTANCE DOCUMENT nrxp20240814d_8k_htm.xml XML 4871
Mailing Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801
Business Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801 484-254-6134
NRX Pharmaceuticals, Inc. (Filer) CIK: 0001719406 (see all company filings)

IRS No.: 822844431 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38302 | Film No.: 241210003
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)